Lysophosphatidic acid mediates fibrosis in injured joints by regulating collagen type I biosynthesis

Osteoarthritis and Cartilage

Volumn 23, Issue 2, 2015, Pages 308-318

  Wu, L ^a   Petrigliano, F A ^a   Ba, K ^a,b   Lee, S ^a   Bogdanov, J ^a   McAllister, D R ^a   Adams, J S ^a,c   Rosenthal, A K ^d   Van Handel, B ^e   Crooks, G M ^a,c   Lin, Y ^b   Evseenko, D ^a,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SICHUAN UNIVERSITY   (China)

^c UCLA Broad Stem Cell Institute for Regenerative Medicine and Stem Cell Research   (United States)

^d MEDICAL COLLEGE OF WISCONSIN   (United States)

^e W E Research   (United States)

Author keywords

Autotaxin; Cartilage injury; Chondrocytes; Collagen type I; Fibrosis; Lysophosphatidic acid

Indexed keywords

COLLAGEN TYPE 1; LYSOPHOSPHATIDIC ACID; PHOSPHATIDYLINOSITOL 3 KINASE; LYSOPHOSPHOLIPID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOSYNTHESIS; BONE MARROW STROMA CELL; CARTILAGE CELL; CARTILAGE INJURY; CONTROLLED STUDY; FIBROCARTILAGE; FIBROSIS; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MALE; MOLECULAR MECHANICS; NONHUMAN; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION; ANIMAL; ARTICULAR CARTILAGE; HINDLIMB; INJURIES; PATHOLOGY; PHYSIOLOGY; SPRAGUE DAWLEY RAT;

ANIMALS; CARTILAGE, ARTICULAR; COLLAGEN TYPE I; FIBROSIS; HUMANS; LYSOPHOSPHOLIPIDS; MALE; RATS; RATS, SPRAGUE-DAWLEY; STIFLE;

EID: 84921051997     PISSN: 10634584     EISSN: 15229653     Source Type: Journal    
DOI: 10.1016/j.joca.2014.11.012     Document Type: Article

References (45)

1. Gelber A.C., Hochberg M.C., Mead L.A., Wang N.Y., Wigley F.M., Klag M.J. Joint injury in young adults and risk for subsequent knee and hip osteoarthritis. Ann Intern Med 2000, 133:321-328.
2. Steadman J.R., Rodkey W.G., Briggs K.K. Microfracture to treat full-thickness chondral defects: surgical technique, rehabilitation, and outcomes. JKnee Surg 2002, 15:170-176.
3. Madry H., Grun U.W., Knutsen G. Cartilage repair and joint preservation: medical and surgical treatment options. Dtsch Arztebl Int 2011, 108:669-677.
4. Mobasheri A., Csaki C., Clutterbuck A.L., Rahmanzadeh M., Shakibaei M. Mesenchymal stem cells in connective tissue engineering and regenerative medicine: applications in cartilage repair and osteoarthritis therapy. Histol Histopathol 2009, 24:347-366.
5. Evseenko D., Latour B., Richardson W., Corselli M., Sahaghian A., Cardinal S., et al. Lysophosphatidic acid mediates myeloid differentiation within the human bone marrow microenvironment. PLoS One 2013, 8:e63718.
6. Aoki J., Inoue A., Okudaira S. Two pathways for lysophosphatidic acid production. Biochim Biophys Acta 2008, 1781:513-518.
7. Umezu-Goto M., Kishi Y., Taira A., Hama K., Dohmae N., Takio K., et al. Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production. JCell Biol 2002, 158:227-233.
8. van Meeteren L.A., Ruurs P., Stortelers C., Bouwman P., van Rooijen M.A., Pradere J.P., et al. Autotaxin, a secreted lysophospholipase D, is essential for blood vessel formation during development. Mol Cell Biol 2006, 26:5015-5022.
9. Gan L., Xue J.X., Li X., Liu D.S., Ge Y., Ni P.Y., et al. Blockade of lysophosphatidic acid receptors LPAR1/3 ameliorates lung fibrosis induced by irradiation. Biochem Biophys Res Commun 2011, 409:7-13.
10. Castelino F.V., Seiders J., Bain G., Brooks S.F., King C.D., Swaney J.S., et al. Amelioration of dermal fibrosis by genetic deletion or pharmacologic antagonism of lysophosphatidic acid receptor 1 in a mouse model of scleroderma. Arthritis Rheum 2011, 63:1405-1415.
11. Pradere J.P., Gonzalez J., Klein J., Valet P., Gres S., Salant D., et al. Lysophosphatidic acid and renal fibrosis. Biochim Biophys Acta 2008, 1781:582-587.
12. Watanabe N., Ikeda H., Nakamura K., Ohkawa R., Kume Y., Aoki J., et al. Both plasma lysophosphatidic acid and serum autotaxin levels are increased in chronic hepatitis C. JClin Gastroenterol 2007, 41:616-623.
13. Choi J.W., Herr D.R., Noguchi K., Yung Y.C., Lee C.W., Mutoh T., et al. LPA receptors: subtypes and biological actions. Annu Rev Pharmacol Toxicol 2010, 50:157-186.
14. Jiang G., Xu Y., Fujiwara Y., Tsukahara T., Tsukahara R., Gajewiak J., et al. Alpha-substituted phosphonate analogues of lysophosphatidic acid (LPA) selectively inhibit production and action of LPA. ChemMedChem 2007, 2:679-690.
15. Eltawil N.M., De Bari C., Achan P., Pitzalis C., Dell'accio F. Anovel invivo murine model of cartilage regeneration. Age and strain-dependent outcome after joint surface injury. Osteoarthritis Cartilage 2009, 17:695-704.
16. Wu L., Bluguermann C., Kyupelyan L., Latour B., Gonzalez S., Shah S., et al. Human developmental chondrogenesis as a basis for engineering chondrocytes from pluripotent stem cells. Stem Cell Reports 2013, 1:575-589.
17. Zheng Z., Yin W., Zara J.N., Li W., Kwak J., Mamidi R., et al. The use of BMP-2 coupled - nanosilver-PLGA composite grafts to induce bone repair in grossly infected segmental defects. Biomaterials 2010, 31:9293-9300.
18. Shaw K.L., Pais E., Ge S., Hardee C., Skelton D., Hollis R.P., et al. Lentiviral vectors with amplified beta cell-specific gene expression. Gene Ther 2009, 16:998-1008.
19. Nikitopoulou I., Kaffe E., Sevastou I., Sirioti I., Samiotaki M., Madan D., et al. Ametabolically-stabilized phosphonate analog of lysophosphatidic acid attenuates collagen-induced arthritis. PLoS One 2013, 8:e70941.
20. Schleicher S.M., Thotala D.K., Linkous A.G., Hu R., Leahy K.M., Yazlovitskaya E.M., et al. Autotaxin and LPA receptors represent potential molecular targets for the radiosensitization of murine glioma through effects on tumor vasculature. PLoS One 2011, 6:e22182.
21. Zhang H., Xu X., Gajewiak J., Tsukahara R., Fujiwara Y., Liu J., et al. Dual activity lysophosphatidic acid receptor pan-antagonist/autotaxin inhibitor reduces breast cancer cell migration invitro and causes tumor regression invivo. Cancer Res 2009, 69:5441-5449.
22. Ferry G., Moulharat N., Pradere J.P., Desos P., Try A., Genton A., et al. S32826, a nanomolar inhibitor of autotaxin: discovery, synthesis and applications as a pharmacological tool. JPharmacol Exp Ther 2008, 327:809-819.
23. Ferguson C.G., Bigman C.S., Richardson R.D., van Meeteren L.A., Moolenaar W.H., Prestwich G.D. Fluorogenic phospholipid substrate to detect lysophospholipase D/autotaxin activity. Org Lett 2006, 8:2023-2026.
24. Kimoto K., Nakatsuka K., Matsuo N., Yoshioka H. p38 MAPK mediates the expression of type I collagen induced by TGF-beta 2 in human retinal pigment epithelial cells ARPE-19. Invest Ophthalmol Vis Sci 2004, 45:2431-2437.
25. Lan C.C., Fang A.H., Wu P.H., Wu C.S. Tacrolimus abrogates TGF-beta1-induced type I collagen production in normal human fibroblasts through suppressing p38MAPK signalling pathway: implications on treatment of chronic atopic dermatitis lesions. JEur Acad Dermatol Venereol 2013.
26. Li N., Cui J., Duan X., Chen H., Fan F. Suppression of type I collagen expression by miR-29b via PI3K, Akt, and Sp1 pathway in human Tenon's fibroblasts. Invest Ophthalmol Vis Sci 2012, 53:1670-1678.
27. Wu L., Gonzalez S., Shah S., Kyupelyan L., Petrigliano F.A., McAllister D.R., et al. Extracellular matrix domain formation as an indicator of chondrocyte dedifferentiation and hypertrophy. Tissue Eng Part C Methods 2014, 20:160-168.
28. Wynn T.A. Cellular and molecular mechanisms of fibrosis. JPathol 2008, 214:199-210.
29. Kalson N.S., Gikas P.D., Briggs T.W. Current strategies for knee cartilage repair. Int J Clin Pract 2010, 64:1444-1452.
30. Li H.Y., Zhang Q.G., Chen J.W., Chen S.Q., Chen S.Y. The fibrotic role of Phosphatidylinositol-3-kinase/Akt pathway in injured skeletal muscle after acute contusion. Int J Sports Med 2013, 34:789-794.
31. Gill T.J., Asnis P.D., Berkson E.M. The treatment of articular cartilage defects using the microfracture technique. JOrthop Sports Phys Ther 2006, 36:728-738.
32. Mithoefer K., Williams R.J., Warren R.F., Potter H.G., Spock C.R., Jones E.C., et al. The microfracture technique for the treatment of articular cartilage lesions in the knee. A prospective cohort study. JBone Joint Surg Am 2005, 87:1911-1920.
33. Asik M., Ciftci F., Sen C., Erdil M., Atalar A. The microfracture technique for the treatment of full-thickness articular cartilage lesions of the knee: midterm results. Arthroscopy 2008, 24:1214-1220.
34. Kreuz P.C., Erggelet C., Steinwachs M.R., Krause S.J., Lahm A., Niemeyer P., et al. Is microfracture of chondral defects in the knee associated with different results in patients aged 40 years or younger?. Arthroscopy 2006, 22:1180-1186.
35. Mithoefer K., McAdams T., Williams R.J., Kreuz P.C., Mandelbaum B.R. Clinical efficacy of the microfracture technique for articular cartilage repair in the knee: an evidence-based systematic analysis. Am J Sports Med 2009, 37:2053-2063.
36. Wu L., Leijten J., van Blitterswijk C.A., Karperien M. Fibroblast growth factor-1 is a mesenchymal stromal cell-secreted factor stimulating proliferation of osteoarthritic chondrocytes in co-culture. Stem Cells Dev 2013, 22:2356-2367.
37. Wu L., Leijten J.C., Georgi N., Post J.N., van Blitterswijk C.A., Karperien M. Trophic effects of mesenchymal stem cells increase chondrocyte proliferation and matrix formation. Tissue Eng Part A 2011, 17:1425-1436.
38. Bluguermann C., Wu L., Petrigliano F., McAllister D., Miriuka S., Evseenko D.A. Novel aspects of parenchymal-mesenchymal interactions: from cell types to molecules and beyond. Cell Biochem Funct 2013, 31:271-280.
39. Aidinis V., Carninci P., Armaka M., Witke W., Harokopos V., Pavelka N., et al. Cytoskeletal rearrangements in synovial fibroblasts as a novel pathophysiological determinant of modeled rheumatoid arthritis. PLoS Genet 2005, 1:e48.
40. Nikitopoulou I., Oikonomou N., Karouzakis E., Sevastou I., Nikolaidou-Katsaridou N., Zhao Z., et al. Autotaxin expression from synovial fibroblasts is essential for the pathogenesis of modeled arthritis. JExp Med 2012, 209:925-933.
41. Zhao C., Fernandes M.J., Prestwich G.D., Turgeon M., Di Battista J., Clair T., et al. Regulation of lysophosphatidic acid receptor expression and function in human synoviocytes: implications for rheumatoid arthritis?. Mol Pharmacol 2008, 73:587-600.
42. Santos A.N., Riemann D., Santos A.N., Kehlen A., Thiele K., Langner J. Treatment of fibroblast-like synoviocytes with IFN-gamma results in the down-regulation of autotaxin mRNA. Biochem Biophys Res Commun 1996, 229:419-424.
43. Kehlen A., Lauterbach R., Santos A.N., Thiele K., Kabisch U., Weber E., et al. IL-1 beta- and IL-4-induced down-regulation of autotaxin mRNA and PC-1 in fibroblast-like synoviocytes of patients with rheumatoid arthritis (RA). Clin Exp Immunol 2001, 123:147-154.
44. Nochi H., Tomura H., Tobo M., Tanaka N., Sato K., Shinozaki T., et al. Stimulatory role of lysophosphatidic acid in cyclooxygenase-2 induction by synovial fluid of patients with rheumatoid arthritis in fibroblast-like synovial cells. JImmunol 2008, 181:5111-5119.
45. Gerwin N., Bendele A.M., Glasson S., Carlson C.S. The OARSI histopathology initiative - recommendations for histological assessments of osteoarthritis in the rat. Osteoarthritis Cartilage 2010, 18(Suppl 3):S24-S34.